natgillin/translations-raw huggingface dataset:
A method for the preparation of a high-energy feed pellet according to any one of the preceding claims, said high-energy feed pellet being based on natural materials in which the starting materials are mixed and processed to obtain a feed pellet, characterised in that the method comprises the following steps: 
Postupak pripreme visoko-energetskih hranjivih peleta prema bilo kojem od prethodnih zahtjeva, te visoko-energetske hranjive pelete su na bazi prirodnih materijala, gdje se početni materijali miješaju i obrađuju da se dobiju hranjive pelete, naznačeno time što postupak obuhvaća sljedeće korake:
The method of claim 1, whereby a drying step is carried out before supplying the material stream to the tablet press. 
Postupak prema zahtjevu 11 ili 12, gdje se korak sušenja provodi prije snabdijevanja pokretnog materijala u prešu za tablete.
first force transmitting means (31) with a distal end section connected to the first sleeve-shaped member (11) and a proximal end section connectable to first operating means (71) of the handle (70); 
prva sredstva za prijenos sile (31) s distalnim krajem spojenim na prvi cjevasti član (11) i proksimalnim krajem koji se može spojiti s prvim operativnim sredstvima (71) drške (70); i
The catheter system (1) according to claim 1, wherein the guiding tube (52) is made from a material allowing the guiding tube (52) to be capable of traversing a tortuous pathway in the body of the patient without kinking. 
Sustav za umetanje (100) prema zahtjevu 1, gdje je provodna cjevčica (52) napravljena od materijala koji omogućuje da provodna cjevčica (52) može prolaziti kroz zavojite putove u tijelu bolesnika uvrtanja.
The catheter system (1) according to claim 4, wherein the second lumen defined by the second catheter tube (42) has a diameter sufficient to accommodate a guide wire (180). 
Sustav za umetanje (100) prema zahtjevu 4, gdje drugi lumen definiran drugom kateterskom cjevčicom (42) ima promjer dovoljan za smještaj provodne žice (180).
The catheter system (1) according to claim 4 or 5, wherein the first catheter tube (32) terminates at its distal end in a flared section, said flared section defining a transition to the first sleeve-shaped member (11) of the seat portion, and wherein the flared section is preferably formed integrally with the distal end section of the first catheter tube (32). 
Sustav za umetanje (100) prema zahtjevu 4 ili 5, gdje prva kateterska cjevčica (32) završava na svom distalnom kraju proširenjem, to proširenje definira prijelaz prema prvom cjevastom članu (11) dijela za smještaj, i gdje je proširenje poželjno formirano integralno s distalnim krajem prve kateterske cjevčice (32).
The catheter system (1) according to one of the claims 4 to 6, wherein the first catheter tube (32) is made from a bendable but inflexible material and wherein at least the proximal end section of the first catheter tube (32) is preferably made of a braided wire construction preferably . 
Sustav za umetanje (100) prema jednom od zahtjeva 4 do 6, gdje je prva kateterska cjevčica (32) napravljena od savitljivog, ali čvrstog materijala i gdje je barem proksimalni kraj prve kateterske cjevčice (32) poželjno napravljen od konstrukcije ispletene žice.
An apparatus as claimed in claim 1 or claim 2, wherein said imaging device is adapted to distinguish between muscle, bone and blood and thus determine if the catheter is being advanced into areas where damage to tissue, such as the walls of veins and arteries, may occur. 
Aparat prema zahtjevu 1 ili zahtjevu 2, pri čemu je spomenuti uređaj za snimanje prilagođen za razlikovanje mišića, kostiju i krvi, a na osnovu toga za određivanje da li se kateter pomiče naprijed u oblast gdje može doći do oštećenja tkiva, kao što su zidovi vena i arterija.
An apparatus as claimed in any preceding claim, wherein the guide passage is provided within the catheter wall. 
Aparat prema bilo kojem od prethodnih zahtjeva, pri čemu se vodeći prolaz nalazi unutar zida katetera.
An apparatus as claimed in claim 7, wherein the imaging device is rotatably mounted within the guide member. 
Aparat prema zahtjevu 7, pri čemu je uređaj za snimanje obrtno montiran unutar vodećeg elementa.
An apparatus as claimed in any preceding claim, wherein the catheter is adapted to be advanced over a cardiac lead (4) to assist removal of the lead. 
Aparat prema bilo kojem od prethodnih zahtjeva, pri čemu je kateter prilagođen za pomicanje naprijed preko srčanog odvoda (4) da bi se olakšalo skidanje odvoda.
An apparatus as claimed in any preceding claim, wherein one or more further tubes or catheters are provided concentrically outside of or inside of the catheter to assist lead removal 
Aparat prema bilo kom od prethodnih zahtjeva, pri čemu se jedna ili više narednih cijevi ili katetera nalaze koncentrično izvan ili unutar katetera da bi se olakšalo skidanje odvoda.
An apparatus as claimed in any preceding claim, further comprising additional lumens or other tubular members within or adjacent to the catheter through which guide wires, stents, and/or balloons may be introduced for other therapeutic modalities, such as for the purpose of evaluating and/or treating coronary artery narrowings or occlusions. 
Aparat prema bilo kojem od prethodnih zahtjeva, koji dalje sadrži dodatne lumene ili druge cjevaste elemente unutar ili u blizini katetera kroz koje se mogu uvesti vodeće žice, stentovi, i/ili baloni za druge terapeutske modalitete, kao što je za svrhe evaluacije i/ili liječenja koronarnih arterijskih suženja ili okluzija.
Cement composition that comprising dopemelanin, as an additive In a maximum percentage of 30% of the cement, this additive substitutes the water of the capillary nets; said cement mixture posses a water/cement relation of 0.2 to 0.4, and optionally it can contain different gravel and sand proportions; said cement mixture generates strong chemical bonds, a higher scouring resistance, at least of the 28% and a higher elastic resistance of the concrete, of at least 50gob, therefore Its cranking in early stages is significantly lower in comparison with conventional concrete. 
Cementni sastav, naznačen time, da sadrži dopamelanin kao aditiv u maksimalnom postotku od 30% od cementa, gdje taj aditiv zamjenjuje mrežu kapilarne vode, dok spomenuta cementna smjesa ima odnos voda/cement od 0,2 do 0,4, te opcijski može sadržavati šljunak i pijesak u različitim mjerama, pri čemu spomenuta cementna smjesa generira jake kemijske veze, veći otpor na ispiranje i to najmanje 28% kao i veći elastični otpor betona od najmanje 50%, te se stoga pucanje u ranim stadijima značajno smanjuje u usporedbi s konvencionalnim betonom.
The use of dopamelanin, as an additive of the cement mixture that substitutes the capillary water proportion in the cement mixture. 
Uporaba dopamelanina, naznačena time, da je on aditiv u cementnoj smjesi koji zamjenjuje udio kapilarne vode u cementnoj smjesi.
The use of dopamelanin in aqueous solution, below 3%, as an agent for setting and curing the concrete, since It significantly Increases the physicochemical and bacteriological properties of the concrete. 
Uporaba dopamelanina u vodenoj otopini, ispod 3%, naznačena time, da je on sredstvo za skrućivanje i sušenje betona, budući da on značajno povećava fizikalno-kemijska i bakteriološka svojstva betona.
A compound of formula I, according to claim 2, wherein R7 and R8, together with the nitrogen to which they are attached, form a 5- or 6-membered saturated heterocycle. 
Spoj formule I, u skladu s patentnim zahtjevom 2, naznačen time što R7 i R8, zajedno s dušikom na kojeg su vezani, tvore 5- ili 6-eročlani zasićeni heterocikl.
A compound of formula I, according to claim 3, wherein said saturated heterocycle is a pyrrolidinyl group. 
Spoj formule I, u skladu s patentnim zahtjevom 3, naznačen time što je navedeni zasićeni heterocikl pirolidinilna skupina.
A compound of formula I, according to claim 1, wherein the compound is selected from the group consisting of: 
Spoj formule I, u skladu s patentnim zahtjevom 1, naznačen time što se spoj bira iz skupine koju čine:
A compound of formula (I), as defined in any one of claims 1 to 10, for use in the treatment of a disorder or condition in a mammal that may be treated by antagonizing histamine-3 receptors. 
Spoj formule (I), u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što je namijenjen upotrebi u liječenju poremećaja ili stanja kod sisavca kojeg se može liječiti antagoniziranjem histaminskih receptora H3.
A compound of formula (I), as defined in any one of claims 1 to 10, for use in the treatment of a disorder or condition in a mammal selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, cognitive disorders, Alzheimer's disease, attention-deficit disorder, attention-deficit hyperactivity disorder, psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy- induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro- intestinal tract. 
Spoj formule (I), u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što je namijenjen upotrebi u liječenju poremećaja ili stanja kod sisavca, koje se bira iz skupine koju čine depresija, poremećaji raspoloženja, shizofrenija, anksiozni poremećaji, kognitivni poremećaji, Alzheimerova bolest, poremećaj nedostatka pažnje, poremećaj nedostatka pažnje uz hiperaktivnost, psihotični poremećaji, poremećaji spavanja, pretilost, vrtoglavica, epilepsija, kinetoza, dišne bolesti, alergija, reakcije dišnih puteva uzrokovane alergijom, alergijski rinitis, nosna kongestija, alergijska kongestija, kongestija, hipotenzija, kardiovaskularna bolest, bolesti GI sustava, hiper- i hipomotilitet i izlučivanje kiseline u gastrointestinalom sustavu.
A compound according to claim 12, wherein the disorder or condition is selected from the group consisting of anxiety disorders, attention-deficit hyperactivity disorder, attention-deficit disorder, respiratory diseases, obesity, cognitive disorders, and psychotic disorders. 
Spoj u skladu s patentnim zahtjevom 12, naznačen time što se poremećaj ili stanje bira iz skupine koju čine anksiozni poremećaji, poremećaj nedostatka pažnje uz hiperaktivnost, poremećaj nedostatka pažnje, dišne bolesti, pretilost, kognitivni poremećaji i psihotični poremećaji.
A compound according to claim 12, wherein the disorder or condition is a respiratory disease selected from the group consisting of adult respiratory distress syndrome, acute respiratory distress syndrome, bronchitis, chronic bronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma, emphysema, rhinitis and chronic sinusitis. 
Spoj u skladu s patentnim zahtjevom 12, naznačen time što poremećaj ili stanje je dišna bolest, koju se bira iz skupine koju čine sindrom dišnog distresa kod odraslih, akutni sindrom dišnog distresa, bronhitis, kronični bronhitis, kronična opstruktivna plućna bolest, cistična fibroza, astma, emfizem, rinitis i kronični sinusitis.
A process for the preparation of a compound according to formula I in claim 1, wherein the process comprises the step of reacting a compound of the formula 4, with an organo metallic reagent derived from a compound of formula 2, followed by the direct amide formation to yield a compound of the formula I. 
Postupak dobivanja spoja formule I u patentnom zahtjevu 1, naznačen time što se postupak sastoji u koraku reakcije spoja formule 4 [image] s organometalnim reagensom dobivenim iz spoja formule 2 [image], uz izravno dobivanje amida kako bi se dobilo spoj formule I.
The transdermal delivery device of claim 1, wherein the opioid agonist and the opioid antagonist cannot be readily indentified by visual inspection. 
Uređaj za transdermalnu dostavu prema patentnom zahtjevu 1, naznačen time da se opioid agonist i opioid antagonist ne mogu lako identificirati vizualnom inspekcijom.
The transdermal delivery device of claims 1-3, wherein the microspheres further comprise a polymer selected from the group consisting of polyesters, polyethers, poly(orthoesters), polysaccharides, cyclodextrins, chitosans, poly (∑-caprolactones), polyanhydrides, albumin, blends and copolymers thereof and mixtures thereof. 
Uređaj za transdermalnu dostavu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time da mikrosfere nadalje sadrže polimer izabran iz skupine koja se sastoji od poliestera, polietera, poli(ortoestera), polisaharida, ciklodekstrina, kitozana, poli (E-kaprolaktona), polianhidrida, albumina, njihovih smjesa i kopolimera te njihovih smjesa.
The transdermal delivery device of claims 1-3, wherein the opioid antagonist becomes releasable if the transdermal delivery device is chewed, soaked, punctured, torn, or subjected to any other treatment which disrupts the integrity of the microspheres. 
Uređaj za transdermalnu dostavu prema patentnom zahtjevu 1, naznačen time da opioid antagonist postaje oslobodiv ukoliko uređaj za transdermalnu dostavu bude žvakan, namočen, probijen, potrgan, ili podilazi bilo kakvom drugom postupku koji naruši integritet mikrosfera.
The transdermal delivery device of claims 1-3, wherein the effect of the opioid agonist is at least partially blocked when the delivery device is chewed, crushed or dissolved in a solvent, or subject to any other treatment which disrupts the integrity of the microspheres, and administered orally, intranasally, parenterally or sublingually. 
Uređaj za transdermalnu dostavu prema patentnom zahtjevu 8, naznačen time da je efekt opioid agonista barem djelomično blokiran kada uređaj za transdermalnu dostavu bude žvakan, smrskan ili otopljen u otapalu, ili podilazi bilo kakvom drugom postupku koji narušava integritet mikrosfera, te je primijenjen oralno, intranazalno, parenteralno ili sublingualno.
a QAM demapper configured to demap constellation values corresponding to Layer 1 signaling data into cell words and to multiplex the demapped cell words into Layer 1 signaling data; 
demaper QAM-a (r713) konfiguriran za demapiranje konstelacijskih vrijednosti koje odgovaraju signalnim podacima razine 1 u stanične riječi i za multipleksiranje demapiranih staničnih riječi u signalni podatak razine 1;
multiplexing the demapped cell words into Layer 1 signaling data; 
multipleksiranje demapiranih staničnih riječi u signalni podatak razine 1;
Pharmaceutical composition comprising a pharmaceutical formulation including an amount of a PDE4 inhibitor, an amount of a HMG-CoA reductase inhibitor and at least one pharmaceutically acceptable auxiliary, wherein the PDE4 inhibitor is 2-{4-[(4aS, 8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-acetamide or a pharmaceutically acceptable salt thereof, the HMG-CoA reductase inhibitor is ATORVASTATIN or a pharmaceutically acceptable salt thereof, and wherein the first amount and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease. 
Farmaceutski sastav, naznačen time, da obuhvaća farmaceutsku formulaciju koja uključuje jednu količinu PDE4-inhibitora, jednu količinu inhibitora reduktaze HMG-CoA i barem jedno farmaceutski prihvatljivo pomoćno sredstvo, pri čemu je PDE4-inhibitor odabran iz skupine koju čine: ROFLUMILAST, farmaceutski prihvatljiva sol od ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljiva sol od ROFLUMILAST-N-oksida, dok inhibitor reduktaze HMG-CoA je ROSUVASTATIN ili njegova farmaceutski prihvatljiva sol, te pritom prva količina i druga količina zajedno sastavljaju učinkovitu količinu za prevenciju ili liječenje upalne plućne bolesti.
Use of a PDE4 inhibitor and a HMG-CoA reductase inhibitor for the manufacture of a medicament, in particular the pharmaceutical composition according to the invention, for the preventive or curative treatment of an inflammatory pulmonary disease, wherein the PDE4 inhibitor is 2-{4-[(4aS, 8aR)-4-(3,4-dimethoxyphenylyl-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-1-piperidin-1-yl}-acetamide or a pharmaceutically acceptable salt thereof and the HMG-CoA reductase inhibitor is ATORVASTATIN or a pharmaceutically acceptable salt thereof. 
Uporaba PDE4-inhibitora i inhibitora reduktaze HMG-CoA, naznačena time, da je za proizvodnju lijeka, posebno farmacetskog sastava prema izumu, za prevenciju ili liječenje upalne plućne bolesti, pri čemu je PDE4-inhibitor odabran iz skupine koju čine: ROFLUMILAST, farmaceutski prihvatljiva sol od ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljiva sol od ROFLUMILAST-N-oksida, a inhibitor reduktaze HMG-CoA je ROSUVASTATIN ili njegova farmaceutski prihvatljiva sol.
Use of a PDE4 inhibitor and a HMG-CoA reductase inhibitor for the manufacture of a sequential or separate co-administrable medicament, in particular the combination product or kit according to the invention, for the preventive or curative treatment of an inflammatory pulmonary disease, wherein the PDE4 inhibitor is 2-{4-[(4aS, 8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-acetamide or a pharmaceutically acceptable salt thereof and the HMG-CoA reductase inhibitor is ATORVASTATIN or a pharmaceutically acceptable salt thereof. 
Uporaba PDE4-inhibitora i inhibitora reduktaze HMG-CoA, naznačena time, da je za proizvodnju dodatnog lijeka koji se daje uzastopno ili odvojeno uz prvi lijek, posebno kombiniranog proizvoda ili garniture prema izumu, za prevenciju ili liječenje upalne plućne bolesti, pri čemu je PDE4-inhibitor odabran iz skupine koju čine: ROFLUMILAST, farmaceutski prihvatljiva sol od ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljiva sol od ROFLUMILAST-N-oksida, a inhibitor reduktaze HMG-CoA je ROSUVASTATIN ili njegova farmaceutski prihvatljiva sol.
one of R3 and R4 is in which n is 1, 2, 3, 4, or 5; each of Ra, Rb, and Rc, independently, is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroalyl, or Rb and Rc, together with the nitrogen atom to which they are attached, form a 3-12 membered saturated, unsaturated, or aromatic ring containing 1-3 heteroatoms selected from N, O and S; and each of Rd and Re, independently, is H, alkyl, alkenyl, or alkynyl; or Rd and Re, together with the nitrogen to which they are attached, form a 3-12 membered saturated, unsaturated, or aromatic ring containing 1-3 heteroatoms selected from N, O, and S; and the other of R3 and R4 is H, halo, nitro, amino, cyano, hydroxy, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, alkoxy, alkylthio, alkylcarbonyl, carboxy, alkoxycarbonyl, carbonylamino, sulfonylamino, aminocarbonyl, or aminosulfonyl; 
jedan od R3 i R4 je [image] gdje n je 1, 2, 3, 4, ili 5; svaki od Ra, Rb, i Rc, nezavisno, je H, alkil, alkenil, alkinil, cikloalkil, heterocikloalkil, aril, ili heteroalil, ili Rb i Rc, zajedno sa atomom dušika na koji su prikvačeni, čine zasićeni, nezasićeni ili aromatski prsten sa 3-12 članova koji sadrži 1-3 heteroatoma izabrana iz N, O i S; te svaki od Rd i Rc, nezavisno, je H, alkil, alkenil, ili alkinil; ili Rd i Rc, zajedno sa atomom dušika na koji su prikvačeni, čine zasićeni, nezasićeni ili aromatski prsten sa 3-12 članova koji sadrži 1-3 heteroatoma izabrana iz N, O i S; te je drugi od R3 i R4 H, halo, nitro, amino, cijano, hidroksi, alkil, alkenil, alkinil, aril, cikloalkil, heterocikloalkil, heteroaril, alkoksi, alkiltio, alkilkarbonil, karboksi, alkoksikarbonil, karbonilamino, sulfonilamino, aminokarbonil, ili aminosulfonil;
The compound of claim 1 or 5 and/or a pharmaceutically acceptable salt thereof, wherein one of R3 and R4 is in which Ra is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl. 
Spoj patentnog zahtjeva 1 ili 5 i/ili njegova farmaceutski prihvatljiva sol, naznačen time da je jedno od R3 i R4 [image] gdje Ra je H, alkil, alkenil, alkinil, cikloalkil, heterocikloalkil, aril, ili heteroaril.
The compound of claim 1 and/or a pharmaceutically acceptable salt thereof, wherein the compound is any of Compounds 1-80, 84-91, 93-101, 103, 104 and 106-170. 
Spoj patentnog zahtjeva 1 i/ili njegova farmaceutski prihvatljiva sol, naznačen time da je spoj bilo koji od spojeva 1-80, 84-91, 93-101, 103, 104 i 106-170.
A pharmaceutical composition, comprising a compound of claim 1 and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier thereof. 
Farmaceutski pripravak, koji sadrži spoj patentnog zahtjeva 1 i/ili njegovu farmaceutski prihvatljivu sol te farmaceutski prihvatljivi nosač istog.
A compound of claim 1 and/or a pharmaceutically acceptable salt thereof for use in treating cancer. 
Spoj patentnog zahtjeva 1 i/ili njegova farmaceutski prihvatljiva sol, za uporabu u liječenju raka.
Use of the Compound of the Formula I for the preparation of a medicament for use in the treatment of an excess of iron in a patient having hereditary hemochromatosis (HH), wherein the treatment of the HH comprises: 
Uporaba, naznačena time, da se spoj formule I: [image] koristi za proizvodnju lijeka za uporabu u liječenju prekomjernog željeza kod pacijenta koji ima nasljednu hemokromatozu (HH), pri čemu to liječenje obuhvaća:
Use according to claim 1 wherein said patient having hereditary hemochromatosis is ineligible for or inadequately treated by phlebotomy. 
Uporaba prema zahtjevu 1, naznačena time, da spomenuti pacijent koji ima nasljednu hemokromatozu, nije prikladan za flebotomiju ili ga je neprikladno tretirati pomoću flebotomije.
Use according to claim 1 or 2 wherein the hereditary hemochromatosis is due to the genetic homozygous mutation C282Y or H63D. 
Uporaba prema zahtjevu 1 ili 2, naznačena time, da nasljedna hemokromatoza se pojavljuje preko genetske homozigotne mutacije C282Y ili H63D.
The compound of claim 1, which is not in salt form. 
Spoj prema patentnom zahtjevu 1, koji nije u obliku soli.
The compound of claims 1 or 2 which is a crystalline form of said compound 
Spoj prema patentnim zahtjevima 1 ili 2 koji je kristalni oblik navedenog spoja.
The compound of claim 2, in a crystalline form comprising the N-1 Form, wherein the N-1 Form is characterized by unit cell parameters substantially equal to the following: 
Spoj prema patentnom zahtjevu 2, u kristalnom obliku koji sadrži N-1 oblik, pri čemu je N-1 oblik naznačen time što su parametri jedinične stanice značajno isti sa slijedećim:
The crystalline form as defined in claim 4 which is characterized by a thermal gravimetric analysis curve in accordance with that shown in Figure 3. 
Kristalni oblik prema patentnom zahtjevu 4 naznačen time što je krivulja termalne gravimetrijske analize u skladu sa onom koja je prikazana na Slici 3.
A compound having the formula: or a salt thereof. 
Spoj koji ima formulu: [image] ili njegova sol.
The pharmaceutical composition of claim 9 further comprising at least one additional therapeutic agent. 
Farmaceutska kompozicija prema patentnom zahtjevu 9 koja dalje sadrži najmanje jedno dodatno terapeutsko sredstvo.
A compound according to claim 9 for use in treating inflammatory diseases, allergic, autoimmune, metabolic, cancer and cardiovascular diseases. 
Spoj prema patentnom zahtjevu 9 za uporabu u liječenju inflamatornih bolesti, alergijskih, autoimunih, metaboličkih bolesti, kancera i kardiovaskularnih bolesti.
Ω is as defined above; and p is 0 or 1. 
Ω jest kao što je gore definirano, te p jest 0 ili 1.
The reconstituted surfactant composition according to claim 8 wherein the analog of the native surfactant protein SP-C is selected from the group consisting of: 
Pripravak rekonstituiranog surfakanta prema patentnom zahtjevu 8, naznačen time da je analog prirodnog surfakanta proteina SP-C odabran iz sljedeće skupine:
The pharmaceutical composition according to claim 14 in the form of either a solution, or dispersion, or suspension or dry powder. 
Farmaceutski pripravak prema patentnom zahtjevu 14, naznačen time da je u obliku otopine, disperzije, suspenzije ili suhog praška.
The pharmaceutical composition according to claim 15 in the form of aqueous suspension. 
Farmaceutski pripravak prema patentnom zahtjevu 15, naznačen time da je u obliku vodene suspenzije.